June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
|Videos|February 6, 2021
Aerie COO: Expanding innovation of glaucoma therapeutics
Author(s)OT Staff Reports
Tom Mitro, president, COO of Aerie Pharmaceuticals, discusses the key highlights from an industry panel discussion titled "Innovate without borders," held during the Glaucoma 360 New Horizons Forum, including the company's role in expanding into the global glaucoma therapeutics market.
Advertisement
Advertisement
Related to this article
Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm Iambic Therapeutics to accelerate small molecule drug discovery.
Offline smartphone AI fundus screening detects diabetic retinopathy, glaucoma, and macular degeneration in one capture, delivering high accuracy for low-resource eye care.
Study finds ChatGPT-5 overpredicts success after macular hole surgery—beating specialists on paper but missing failures.
Diana Canto-Sims, OD, owner of Buena Vista Optical, discusses how Meta's donation of free AI glasses to blind veterans could close longstanding access gaps in low vision care—and where voice-command wearables fit alongside traditional rehabilitation tools.
A large real-world cohort study finds OSA is associated with elevated glaucoma risk, though whether positive airway pressure therapy itself plays a role remains unclear.
ARPA-H funds OCULAB to build tear-duct sensors that track biomarkers in real time and microdose drugs, transforming dry-eye and systemic care.
A retrospective study finds that direct selective laser trabeculoplasty significantly lowers intraocular pressure, with the greatest benefit seen in treatment-naive eyes.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
AAO 2026: Tinlarebant in Stargardt disease: Jacque Duncan, MD, on DRAGON results
2
AAO 2026: Vamikibart shows sustained gains in uveitic macular edema as FDA accepts BLA
3
PRIMA at 3 years: Early surgical risk, durable vision gains in GA
4
AAO 2026: What the evidence really shows about nutrition and the eye
5